@article{oai:uoeh-u.repo.nii.ac.jp:00000727,
 author = {石橋 , 真吾 and 近藤  , 寛之 and Ishibashi, Shingo and Kondo, Hiroyuki},
 issue = {4},
 journal = {産業医科大学雑誌, Journal of UOEH},
 month = {Dec},
 note = {血管新生緑内障は，網膜の虚血性変化により血管内皮増殖因子（vascular endothelial growth factor ; VEGF）が産生され，虹彩や前房隅角に新生血管が形成されると考えられている．血管新生緑内障に，抗VEGF抗体であるbevacizumabを硝子体内注射すると，細隙灯顕微鏡検査で虹彩や前房隅角の新生血管が消退すると報告されている．しかし，蛍光前眼部造影検査を用いて観察すると，bevacizumabは，新生血管そのものを消退させるのではなく，新生血管の透過性を減少させることが分かった．本総説では，血管新生緑内障の病態と診断，bevacizumab硝子体内注射による虹彩と前房隅角の新生血管に及ぼす影響について詳述する
Neovascular glaucoma is a serious complication associated with retinal ischemic changes, which increase the production of vascular endothelial growth factor. Vascular endothelial growth factor has been implicated as a key molecule in the development of newly formed vessels and neovascular glaucoma. Intravitreal injection of bevacizumab, a full-length humanized anti-vascular endothelial growth factor monoclonal antibody, leads to a dramatic regression of the new iris and iridocorneal angle vessels on slitlamp examination. However, anterior segment angiography reveals that bevacizumab does not cause a regression of the neovascular vessels themselves but reduces vascular permeability while newly formed vessels are still present in the iris and iridocorneal angle. This review focuses on the pathology and diagnosis of neovascula glaucoma and the effect of intravitreal bevacizumab on the iris and iridocorneal angle neovascularization.},
 pages = {299--304},
 title = {Bevacizumab硝子体内注射による血管新生緑内障の新生血管への影響},
 volume = {37},
 year = {2015},
 yomi = {イシバシ, シンゴ and コンドウ, ヒロユキ}
}